Published in:
25-04-2022 | Herpes Virus | Clinical Brief
Rituximab as Second-Line Treatment in Anti-NMDAR Encephalitis after Herpes Simplex Encephalitis in Children
Authors:
Paula Carrascosa-García, Lidia Oviedo-Melgares, David Torres-Fernández, Daniel Blázquez-Gamero, Thaís Armangué, Sara Vila-Bedmar, Luis Prieto-Tato, Concepción Miranda-Herrero, Mar Santos-Sebastián, Elena María Rincón-López, Elisa Fernández-Cooke
Published in:
Indian Journal of Pediatrics
|
Issue 10/2022
Login to get access
Abstract
The long-term response of two infants with anti-N-methyl-D-aspartate receptor (anti-NMDAR) post herpes simplex encephalitis treated with rituximab is reported here. Rituximab may improve the course of the disease and should be considered early as second-line treatment. Data on the long-term effect of rituximab in B cell depletion and immunoglobulins levels in infants are needed.